Access Pathways for Innovative Medicines in China: Hospitals, Pharmacies, and Pharmaceutical Distribution Channels

More and more overseas patients are beginning to explore China’s innovative drug resources in search of new treatment opportunities.

However, for international patients, the real challenge is often not whether the medicines exist, but rather:

How can innovative medicines in China actually be accessed? 🌏

In reality, different types of innovative medicines in China involve completely different access methods and treatment pathways.

Currently, the main access pathways for innovative medicines in China can generally be divided into three categories: 🔽

• China hospital channels
• China pharmacy channels
• China pharmaceutical distribution channels

Different channels are suitable for different patient groups, treatment stages, and clinical scenarios.

China Hospital Channels: Suitable for Initial Treatment and Complex Cases

For many international patients, Chinese hospitals remain the primary entry point for accessing innovative medicines in China.

Especially for treatments that require full physician supervision — such as CAR-T cell therapy, bispecific antibodies, certain immunotherapies, and injectable innovative drugs — patients often need to complete medical evaluations, treatment planning, and administration within the hospital system.

Many overseas patients have already undergone multiple rounds of treatment in their home countries with limited results, which is why they begin exploring whether China offers alternative or more advanced treatment options.

In most cases, patients first submit medical records, imaging results, and genetic testing reports through remote consultation services. Chinese physicians then evaluate whether further treatment in China may be appropriate.

If the patient qualifies, the next steps may include medical travel to China, inpatient management, multidisciplinary consultations, and individualized treatment planning.

Large Chinese tertiary hospitals have accumulated extensive clinical experience in lung cancer, liver cancer, gastric cancer, pancreatic cancer, and hematologic malignancies, while also maintaining strong innovative drug and clinical research resources.

For patients with complex diseases, hospital-based access pathways for innovative medicines in China provide far more than simply obtaining a medication. They offer comprehensive treatment capabilities, including:

• Physician team evaluations
• Second medical opinions
• MDT multidisciplinary consultations
• Innovative treatment planning
• Treatment process management
• Ongoing efficacy monitoring

As a result, hospital channels are generally more suitable for newly diagnosed patients, complex cases, and patients who need to redesign or adjust their treatment strategies.

Hospital-based access pathways for innovative medicines in China are particularly important for patients seeking advanced oncology treatment and personalized medicine approaches.

China Pharmacy Channels: Suitable for Long-Term Medication and Outpatient Refills

In addition to hospitals, an increasing number of innovative medicines in China are now available through licensed pharmacies and DTP (Direct-to-Patient) pharmacy systems.

For certain oral targeted therapies, chronic disease medications, and self-paid oncology drugs, pharmacy channels have become an important solution for long-term treatment management.

For patients with stable diagnoses and established treatment plans, pharmacy access is often more flexible and convenient.

For example, some patients complete their initial evaluations and treatment planning in Chinese hospitals, but their primary concern afterward becomes how to maintain a stable and continuous drug supply over the long term.

Compared with frequent hospital visits, obtaining medications through pharmacy systems can be significantly more convenient.

Unlike traditional retail pharmacies, DTP pharmacies are more specialized in oncology medicines, innovative therapies, and chronic disease management. They also provide more professional pharmaceutical services, prescription review, and patient follow-up support.

For international patients, pharmacy-based access pathways for innovative medicines in China primarily address one critical issue: long-term and stable medication supply.

This is especially important for patients receiving targeted therapies or chronic innovative treatments that require continuous administration rather than one-time intervention.

At the same time, international patients obtaining medicines through pharmacy channels may also need support with:

• Prescription requirements
• International shipping arrangements
• Cold-chain transportation
• Medication guidance
• Translation of medication instructions
• Long-term refill coordination

Therefore, pharmacy channels are not simply about purchasing medication. They are more accurately described as long-term medication management and outpatient treatment support systems.

For patients with confirmed treatment plans who require continuous therapy, pharmacy-based access pathways for innovative medicines in China are often a highly practical option.

China Pharmaceutical Distribution Channels: Suitable for Overseas Long-Term Supply

For patients who are unable to remain in China for long-term treatment, international pharmaceutical distribution channels can help support continued therapy overseas.

In recent years, many international patients have become increasingly interested in innovative medicines in China. However, practical challenges quickly emerge:

🤔 Some medications have not yet been officially launched in local markets, some regions continue to experience drug shortages, and some patients are unable to travel to China frequently for ongoing treatment.

Under these circumstances, pharmaceutical distribution services are becoming increasingly important within the broader access pathways for innovative medicines in China.

However, many people mistakenly assume that pharmaceutical distribution simply means “procurement and shipping.” In reality, for innovative therapies, the most complicated part is often not the purchasing process itself, but the entire cross-border medical supply chain that follows.

This is particularly true for biologics, injectable medications, and temperature-sensitive therapies, which often require highly controlled transportation conditions.

The overall process may involve:

• Drug procurement and coordination
• Regulatory export procedures
• International logistics
• Cold-chain transportation
• Customs documentation
• Cross-border supply management
• Long-term stable drug supply

For many overseas patients, the key concern is not simply whether a medicine can be obtained, but whether it can be supplied safely, consistently, and sustainably over time.

As more innovative medicines in China gain international attention, global demand for innovative drug access and cross-border pharmaceutical support services continues to grow.

Cross-border access pathways for innovative medicines in China are becoming increasingly relevant for international oncology patients and long-term treatment management.

Which Access Pathway Is More Suitable for You?

Different patients may require completely different approaches when navigating access pathways for innovative medicines in China.

In many cases, patients may use multiple channels during different stages of treatment.

For example, some patients may first complete evaluations and initial treatment through Chinese hospitals, and later continue long-term therapy through pharmacy systems or pharmaceutical distribution channels.

🎯 Therefore, the most important factor is not choosing a single channel, but identifying the most appropriate access pathway based on the patient’s current treatment stage and clinical needs.

Access Method	Suitable Patients	Access Process	Advantages	Limitations
China Hospital Channels	Newly diagnosed patients, complex cases, patients needing treatment adjustments	Physician evaluation → Remote consultation / Medical travel to China → Hospital treatment	Comprehensive treatment planning, multidisciplinary consultations, innovative therapy opportunities	Requires hospital evaluation and relatively longer process
DTP Pharmacy Channels	Diagnosed patients requiring long-term stable medication	Physician prescription → Pharmacy review → Long-term outpatient medication supply	Strong treatment continuity, professional pharmaceutical support, suitable for long-term therapy	Requires confirmed diagnosis and prescription
China Pharmaceutical Distribution Channels	Patients unable to remain in China and requiring cross-border long-term medication supply	Compliant procurement → Export procedures → International logistics delivery	Enables cross-border medication access and overseas treatment continuity	Involves regulatory and logistics complexity

How DengYueMed Supports International Patients Accessing Innovative Medicines in China

HongKong DengYue Medicine is committed to helping international patients connect with innovative medicines in China and related healthcare resources.

Unlike traditional medical intermediaries or standalone medication procurement services, DengYueMed simultaneously connects:

• Chinese hospital resources
• Pharmacy and DTP systems
• China pharmaceutical distribution channels

✅ Based on different medical conditions, treatment stages, and geographic regions, DengYueMed helps patients identify more appropriate access pathways for innovative medicines in China.

Services include:

• China hospital coordination
• International patient support
• Innovative drug consultation
• Pharmacy purchasing assistance
• International pharmaceutical distribution
• Cold-chain transportation support
• Medical travel assistance to China

Helping overseas patients more efficiently understand and connect with innovative treatment resources in China.

Conclusion

As China’s innovative pharmaceutical industry continues to develop, access pathways for innovative medicines in China are becoming increasingly diversified for international patients.

From hospital-based treatment and long-term pharmacy supply to pharmaceutical distribution services, China is gradually building a more comprehensive international innovative medicine access system.

For overseas patients, understanding the differences between these access pathways can help improve treatment planning and long-term medication continuity.

If you would like to learn more about access pathways for innovative medicines in China, DTP pharmacy services, or cross-border medication support solutions, please contact the DengYueMed team for further professional assistance and information.

FAQ about Access Pathways for Innovative Medicines in China